Optimizing Hypertension Management with Olmesartan and Atenolol

Rationale for Dose Optimization

The American Heart Association recommends optimizing doses of current medications before adding or switching drug classes, and for non-Black patients with uncontrolled hypertension on an ARB plus another agent, the sequence is to increase the ARB to full dose before making other changes 2, 1
The International Society of Hypertension guidelines position beta-blockers as fourth- or fifth-line agents, reserved for resistant hypertension or specific indications, and should not be abruptly discontinued without compelling reasons 2, 1

Increase olmesartan from 20mg to 40mg once daily while maintaining the current atenolol dose, and reassess blood pressure within 2-4 weeks after the dose increase, with the goal of achieving target BP (<140/90 mmHg minimum, ideally <130/80 mmHg) within 3 months of treatment modification 1, 2
If blood pressure remains uncontrolled after optimizing olmesartan to 40mg, add a thiazide or thiazide-like diuretic as the third agent (hydrochlorothiazide 12.5-25mg or chlorthalidone 12.5-25mg daily), creating the evidence-based triple therapy combination: ARB + beta-blocker + thiazide diuretic 2, 1, 3

Check blood pressure within 2-4 weeks of increasing olmesartan to 40mg, and monitor serum potassium and creatinine 1-4 weeks after uptitrating olmesartan 1
Assess for olmesartan-specific adverse effects including dizziness, hyperkalemia, and acute kidney injury 1

Abrupt atenolol discontinuation can precipitate severe cardiovascular complications, including angina exacerbation, myocardial infarction, and ventricular arrhythmias, even in patients without known coronary disease 2, 1
Adding a third drug class before maximizing doses of the current two-drug regimen violates guideline-recommended stepwise approaches and may expose patients to unnecessary polypharmacy 1
Before intensifying therapy, confirm medication adherence and rule out secondary causes of hypertension, and consider home blood pressure monitoring or 24-hour ambulatory monitoring to confirm sustained hypertension 1, 4, 2